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Abstract
Objective: Intraspinal human spinal cord-derived neural stem cell (HSSC)
transplantation is a potential therapy for amyotrophic lateral sclerosis (ALS);
however, previous trials lack controls. This post hoc analysis compared ambula-
tory limb-onset ALS participants in Phase 1 and 2 (Ph1/2) open-label intrasp-
inal HSSC transplantation studies up to 3 years after transplant to matched
participants in Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT)
and ceftriaxone datasets to provide required analyses to inform future clinical
trial designs. Methods: Survival, ALSFRS-R, and a composite statistic (ALS/
SURV) combining survival and ALS Functional Rating Scale revised (ALSFRS-
R) functional status were assessed for matched participant subsets: PRO-ACT
n = 1108, Ph1/2 n = 21 and ceftriaxone n = 177, Ph1/2 n = 20. Results: Sur-
vival did not differ significantly between cohorts: Ph1/2 median survival
4.7 years, 95% CI (1.2, ∞) versus PRO-ACT 2.3 years (1.9, 2.5), P = 1.0; Ph1/
2 3.0 years (1.2, 5.6) versus ceftriaxone 2.3 years (1.8, 2.8), P = 0.88. Mean
ALSFRS-R at 24 months significantly differed between Ph1/2 and both compar-
ison cohorts (Ph1/2 30.1  8.6 vs. PRO-ACT 24.0  10.2, P = 0.048; Ph1/2
30.7  8.8 vs. ceftriaxone 19.2  9.5, P = 0.0023). Using ALS/SURV, median
PRO-ACT and ceftriaxone participants died by 24 months, whereas median
Ph1/2 participant ALSFRS-Rs were 23 (P = 0.0038) and 19 (P = 0.14) in PRO-
ACT and ceftriaxone comparisons at 24 months, respectively, supporting
improved functional outcomes in the Ph1/2 study. Interpretation: Comparison
of Ph1/2 studies to historical datasets revealed significantly improved survival
and function using ALS/SURV versus PRO-ACT controls. While results are
encouraging, comparison against historical populations demonstrate limitations
in noncontrolled studies. These findings support continued evaluation of HSSC
transplantation in ALS, support the benefit of control populations, and enable
necessary power calculations to design a randomized, sham surgery-controlled
efficacy study.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal disease
involving progressive motor neuron degeneration.1 The
complex pathogenesis and limited efficacy of disease-
modifying therapies predicates an urgent need for novel
treatment strategies. Recent studies examining cellular
transplantation for neurological disorders2 prompted
interest in cell-based therapies for ALS, and several cell
types and delivery strategies are being evaluated in pre-
clinical and translational ALS studies.3,4
Human spinal cord-derived neural stem cell (HSSC)
intraspinal transplantation as a therapeutic approach has
progressed to clinical trials in ALS patients. This approach
is supported by in vitro and in vivo preclinical studies5–9
and demonstrated safety of HSSC intraspinal transplanta-
tion in Gottingen minipigs,10,11 data which secured Food
& Drug Administration approval to examine HSSC
intraspinal transplantation in ALS patients.
We completed Phase 112–15 and 216 HSSC intraspinal
transplantation trials in ALS patients. Phase 1 evaluated
the feasibility of injecting HSSCs directly into lumbar
(L2–L4) or cervical (C3–C5) spinal cord regions in 15
ALS participants following a “risk escalation” paradigm.
These spinal segments were chosen with the goal of main-
taining participant function, as lumbar regions control
ambulation and cervical regions control respiration. Phase
2 evaluated the safety of transplanting 2–8 million HSSCs
into the cervical (C3–C5) region in 15 additional partici-
pants, with three participants also undergoing lumbar
(L2–L4) transplantation of an additional 8 million
HSSCs.
The Phase 1 and 2 (Ph1/2) trials confirmed the safety
of HSSC transplantation, but participant numbers were
small and the trials lacked a placebo arm. To determine
the potential effect size for a future larger placebo-con-
trolled Phase 3 trial, we compared long-term clinical out-
comes and survival of our study cohort – Ph1/2
ambulatory limb-onset ALS participants receiving intrasp-
inal HSSC transplantation (referred to as HSSC Ph1/2) –
to two historical cohorts of similar ALS participants. This
article extends our most recent report16 by performing a
hypothesis-based post hoc analysis on ambulatory limb
onset participants using a matching algorithm while also
examining all available long-term safety data on surviving
trial participants as a further step towards conducting a
Phase 3 trial. Finally, and in contrast with the most recent
publication, the long-term data allow us to look for
potential efficacy windows of this cellular treatment strat-
egy and underscore the utility of a combined function
and survival statistic.
Methods
HSSC Ph1/2 participants
The HSSC product,17 surgical methods,14,15 participant
selection, immunosuppression regimen, and study activi-
ties are previously described.12,13,16 Phase 1, conducted
at Emory University, followed a “risk escalation” design
with 15 participants. To minimize potential procedure
complications, the initial six participants were nonam-
bulatory and received lumbar injections, while later
groups enrolled more functional ambulatory partici-
pants.3 Phase 2, conducted at Emory University (seven
participants), the University of Michigan (six partici-
pants), and Massachusetts General Hospital (two partic-
ipants), was a multicenter dose escalation study.3,16
Two ambulatory subjects had bulbar onset. The present
post hoc analysis only included ambulatory Ph1/2 par-
ticipants with limb-onset disease, as nonambulatory par-
ticipants with advanced disease and bulbar-onset
participants are less likely to benefit from this therapeu-
tic approach targeting spinal motor neurons. Hence,
only 22 of the 30 Ph1/2 subjects were eligible to be
included in this analysis.
Control groups
HSSC Ph1/2 were open-label feasibility/safety studies
without a control population and were not powered to
demonstrate efficacy. Nevertheless, similar to our prior
analysis,16 to gain insight into potential benefit and
plan for a future trial, participants from the Pooled
Resource Open-Access ALS Clinical Trials (PRO-ACT)
dataset18,19 and the ceftriaxone trial (dataset provided
by the Northeast ALS Consortium)20 served as historical
controls. The PRO-ACT dataset contains open-access
ALS Functional Rating Scale revised (ALSFRS-R) and
survival data for over 10,723 participants from 23 Phase
2 and 3 ALS trials conducted between 1990 and 2013,
including the ceftriaxone cohort.18,19,21 The large data
volume collected under controlled environments justifies
its use as a noncontemporaneous historical dataset.
PRO-ACT participants were included only if they con-
tained data on age, gender, disease duration, and an
ALSFRS-R score within 1 month of when records were
first available to use as a baseline. The ceftriaxone
study, conducted between 2006 and 2012, contained
fewer ALS participants but represents a more recent
cohort, justifying a separate analysis.20 For both data-
sets, >1 month follow-up data were required for inclu-
sion in our analysis.
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Matching procedure
A matching procedure selected historical participants
based on same gender, age difference ≤5 years, difference
in baseline ALSFRS-R scores ≤5, and difference in time
from symptom onset ≤6 months. Ph1/2 participants were
included in the analysis if they matched at least one par-
ticipant in the comparison study and, conversely, com-
parison study participants were included if they matched
at least one Ph1/2 participant. As a result of matching, 21
Ph1/2 subjects were compared to 1108 PRO-ACT sub-
jects, and 20 Ph1/2 subjects were compared to 177 ceftri-
axone subjects (the Ph1/2 subjects without any matches
had long onset durations).
Survival and ALS/SURV assessments
Kaplan–Meier survival curves were compared by the Wil-
coxon statistic. Survival time was referenced to day of
first surgery for Ph1/2 participants, the first ALSFRS-R
measurement in PRO-ACT, and the baseline visit for cef-
triaxone. PRO-ACT matches were required to have a
ALSFRS-R observation within the first 30 days and a sec-
ond observation at greater than 30 days. Ceftriaxone
matches were required to have an ALSFRS-R observation
within 0.1 years from the baseline visit and at least 1 fol-
low-up after 0.1 years. Means of ALSFRS-R at each fol-
low-up interval, without imputation, were calculated and
compared with t-tests.
To incorporate functional outcomes in addition to sur-
vival, we utilized an ALSFRS-R/survival composite mea-
sure (ALS/SURV), a novel analysis method that is a
simplification of the combined assessment of function
and score (CAFS) algorithm.22 In this method, all partici-
pants are ranked at each time point by ALSFRS-R or time
to death, allowing calculation of meaningful confidence
intervals in terms of ALSFRS-R score and/or length of
survival. Specifically, ALS/SURV at each time point repre-
sented either (1) ALSFRS-R if the participant was alive,
or (2) a negative value if the participant was deceased,
where the earliest death was assigned the most negative
value and the most recent death the smallest negative
value. ALSFRS-R was determined at baseline and 6, 12,
18, and 24 months for each participant using (1) the
exact value when the participant’s visit was within
0.15 years of the time point or (2) linear interpolation
when the participant had ALSFRS-R values before and
after the time point. Interval windows were defined as
0.15 years based on the ceftriaxone dataset where time
was rounded to tenths of a year; thus, a 0.1-year differ-
ence could be as high as 0.15 prior to rounding. Consid-
ering this window, a 6-month visit could occur between
0.35 and 0.65 years (4.2–7.8 months), and a 2-year visit
between 1.85 and 2.15 years. When the participant was
lost to follow-up but not deceased, the participant was
treated as lost to follow-up from that point forward.
Therefore, in our analysis the ALS/SURV composite score
is equal to the current ALSFRS-R score when the partici-
pant is alive or equal to (maximum length of follow-
up) + (length of survival in years) if the participant died.
When ranking ALS/SURV values, the highest rank was
assigned to the participant with the highest ALSFRS-R
value and the lowest rank to the first participant who
died. Therefore, all deceased participants at the specified
time point will have lower ranks than all participants still
alive.
Consider the 24-month time point. At this time point,
many subjects have died, but others are still alive and
have ALSFRS-R values. Those who have died can be
ordered by time of death from shortest to longest (nearest
24 months) and ranked from 1 to D where D is the num-
ber of deaths. Those who are alive and are assessed at
24 months can be ordered by their ALSFRS-R tests from
lowest to highest and ranked from D + 1 to N where N
is the total number of subjects evaluated at 24 months.
For ease of interpretation, the ranks were divided by
N + 1 to put them on a scale of 0 to 1, with a mean
value of 0.5. A Mann–Whitney-Wilcoxon rank sum test
can then compare the two groups. This analysis at each
time point using complete data (omitting subjects who
have not died but do not have an ALSFRS-R score at that
time point) is presented.
While the above analysis only includes subjects who
have died or have data at the time point, we also took an
imputation approach. In ALS, a reasonable assumption
for subjects without data is that their progression would
have been similar to the subjects who continue to be fol-
lowed. This can be imputed by assigning subjects who do
not have values in the percentile that they had at the last
time when they were observed. For example, if a subject
was at the median of all subjects when last observed, then
the subject will be imputed to remain at the 50th per-
centile relative to all the subjects at each subsequent time
point. This analysis with imputed data is also presented.
Clinical safety
Available Ph1/2 safety data through August 2017 were
examined for adverse events (AEs) using our previously
described paradigm.16
Power analysis and statistics
The method described in this paper orders the data values
by percentiles. Any other monotonic ordering yields the
same results for nonparametric tests (such as the
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Wilcoxon test). When the percentiles are replaced by their
normal deviates, the resulting data values are normally
distributed with a standard deviation of one. The differ-
ence in means of the normal deviates between the groups
is the empirical (observed) effect size. We performed this
modified analysis for the groups in this paper to provide
an estimate of the effect size.
Statistical analyses utilized SAS 9.4 (SAS Institute, Cary,
NC). Graphs were plotted with GraphPad Prism (Graph-
Pad Software, La Jolla, CA).
Results
Cohorts
Phase 1 enrolled 15 participants, but the first six were
excluded from the post hoc analysis as they represented a
feasibility cohort of nonambulatory, late-stage participants
(three had tracheostomies). Phase 2 enrolled 15 partici-
pants, although two subjects with bulbar-onset disease
were excluded. This resulted in 22 Ph1/2 participants
(Table 1) for our current evaluation of long-term follow-
up. As this window extended beyond our previously
reported safety data,16 an updated summary of frequent
AEs and serious AEs for the Phase 2 study through
August 2017 is included (Table S1). There were no
changes to the two previously reported serious AEs16
(subject 312 remains weaker than presurgical baseline and
subject 315 continues to have neuropathic pain). Across
the two Phases there were 16 deaths through August 2017
(Table S2): one was attributed to a fatal arrhythmia (due
to undiagnosed cardiac hypertrophy), one was due to
glioblastoma (pathology confirmed the tumor was of
patient origin, deeming it unrelated to study drug or
immunosuppression), and the remaining were associated
with respiratory failure secondary to ALS progression. No
deaths were attributed to the HSSCs, surgical device, sur-
gical procedure, or immunosuppression paradigm, sup-
porting the safety of HSSC transplantation for ALS.
PRO-ACT and ceftriaxone data were utilized for histor-
ical control populations. The PRO-ACT dataset contained
3344 participants with complete data on gender, age, dis-
ease duration, and, if relevant, time to death (Table 1A).
After eliminating those with bulbar-onset disease and
matching the PRO-ACT subjects to Ph1/2 subjects, 1108
PRO-ACT participants remained (Table 1B). There were
no significant differences between matched groups for
gender (P = 1.00 Fisher’s exact test), age, duration from
symptom onset, and baseline ALSFRS-R (P = 0.12, 0.13,
and 0.17, respectively, two-tailed two-sample t-test with
unequal variances).
The ceftriaxone dataset contained 507 participants with
follow-up data (Table 1A). After eliminating those with
bulbar-onset disease and matching to the Ph1/2 subjects,
177 participants remained (Table 1B). There were no sig-
nificant differences between matched groups for gender
(P = 1.00 Fisher’s exact test), age, duration from symp-
tom onset, and baseline ALSFRS-R (P = 0.10, 0.23 and
0.83, respectively, two-tailed two-sample t-test with
unequal variances).
Table 1. Cohort demographics.
(A) Complete cohorts
Characteristic Ph1/2 PRO-ACT
P-value PRO-ACT
versus Ph1/2 Ceftriaxone
P-value ceftriaxone
versus Ph1/2
Subjects (number) 30 3344 507
Age, years (SD) 50.0  9.9 55.7  11.3 0.0038 55.4  10.4 0.0070
Baseline ALSFRS-R (SD) 32.8  9.6 37.9  5.4 0.0072 36.4  5.9 0.053
Disease duration, years (SD) 2.6  2.8 1.6  0.9 0.060 1.6  0.7 0.058
Male (%) 83.3 62.8 0.022 60.5 0.012
Bulbar onset (%) 6.7 20.5 0.068 22.9 0.040
(B) Matched cohorts to ambulatory limb-onset Ph1/2 participants
Characteristic Ph1/2 PRO-ACT
P-value PRO-ACT
versus Ph1/2 Ph1/2 Ceftriaxone
P-value ceftriaxone
versus Ph1/2
Subjects (number) 21 1108 - 20 177 -
Age, years (SD) 49.2  10.5 52.9  9.7 0.12 49.6  10.6 53.3  9.4 0.10
Baseline ALSFRS-R (SD) 36.5  5.4 38.1  4.7 0.17 36.9  5.3 36.7  4.8 0.83
Disease duration, years (SD) 1.7  1.1 1.3  0.6 0.13 1.5  0.8 1.4  0.6 0.23
Male (%) 85.7 86.4 1.00 85.0 85.9 1.00
Bulbar onset (%) 0.0 0.0 n/a 0.0 0.0 n/a
PRO-ACT, Pooled Resource Open-Access ALS Clinical Trials; ALSFRS-R, ALS Functional Rating Scale revised.
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Survival analysis
Survival did not differ significantly between ambulatory
limb-onset Ph1/2 or matched PRO-ACT and ceftriaxone
participants: Ph1/2, n = 21, median survival (MS)
4.7 years, 95% CI (1.2, ∞) versus PRO-ACT, n = 1108,
MS 2.3 years, 95% CI (1.9, 2.5), Wilcoxon P = 1.0; Ph1/
2, n = 20, MS 3.0 years, 95% CI (1.2, 5.6) versus ceftriax-
one, n = 177, MS 2.3 years, 95% CI (1.8, 2.8), Wilcoxon
P = 0.88 (Figs. 1, 2, Table 2). Survival curves deviated in
the Ph1/2 and comparison cohorts after 2 years.
ALSFRS-R
Baseline ALSFRS-R comparing the ambulatory limb-onset
Ph1/2 participants to the PRO-ACT and ceftriaxone
cohorts were 36.5  5.4 versus 38.1  4.7 (P = 0.17) and
36.9  5.3 versus 36.6  4.9 (P = 0.84), respectively
(Table 2A). At 24 months, ALSFRS-R in Ph1/2 compared
to PRO-ACT and ceftriaxone cohorts was 30.1  8.6 ver-
sus 24.0  10.2 (P = 0.048) and 30.7  8.8 versus
19.2  9.5 (P = 0.0023), respectively.
ALS/SURV analysis
ALS/SURV ranking was required for the PRO-ACT and
ceftriaxone comparisons due to the lack of a survival dif-
ference (Figs. 1, 2, Table 2). Table 2A presents the mean
ALSFRS-R at each follow-up interval. Table 2A and C
represent the median of the ALS/SURV score, which can
be either an ALSFRS-R score or length of survival (year),
and the 25–75% interquartile range (IQR). For example,
if the 25th percentile is 1.4 years, then 25% of the partici-
pants died within 1.4 years. Table 2B presents the median
and IQR of the ALS/SURV statistic when only observed
values are used. Table 2C presents these statistics when
missing values for subjects are imputed as if the subjects
progressed at the same rate as the overall group; that is,
remained at the same percentile as when they became lost
to follow-up.
Using only observed data, the median Ph1/2 partici-
pant’s ALS/SURV at 24 months was an ALSFRS-R of 23
(IQR 1.2 years, 33), whereas the median PRO-ACT par-
ticipant died at 1.2 years (IQR 0.8 year, 10) (P = 0.0038)
(Table 2B). With imputation, the median Ph1/2 partici-
pant had a ALS/SURV of 15 (IQR 1.2 years, 29) and the
median PRO-ACT participant died at 1.35 years (IQR
0.9 year, 16) (P = 0.023) (Table 2C).
For the matched ceftriaxone comparison, the median
Ph1/2 participant’s ALS/SURV was 19 (IQR 1.2 years, 33)
at 24 months compared to 1.7 years (IQR 1.2 years, 16)
in ceftriaxone (P = 0.14) (Table 2B). When values were
imputed for lost to follow-up cases, the ALS/SURV was
18 (IQR 1.2 years, 31) for the median Ph1/2 participants
and 1.8 years (IQR 1.35 years, 17) for the median ceftri-
axone participant (P = 0.14) (Table 2C).
At baseline and at 6 months, PRO-ACT had a higher
average rank than Ph1/2. However, by 12-months this is
reversed and Ph1/2 has a higher average rank than PRO-
ACT; that is, for survivors Ph1/2 has a better long-term
outcome than PRO-ACT.
As ceftriaxone did not demonstrate a treatment effect,
we decided to analyze all matching participants, but for
completeness, also performed separate analyses on the
placebo arm that contained 171 participants with follow-
up data, 64 of which remained after matching to limb-
onset Ph1/2 subjects. There were no significant differences
in gender, age, disease duration, or baseline ALSFRS-R
between these groups (data not shown). Likewise, no dif-
ferences in our survival and functional assessments were
detected (data not shown).
Power analysis
The 24-month comparisons with matched Ph1/2 subjects
yielded effect sizes of 0.74 and 0.49 for PRO-ACT subjects
(without and with imputation, respectively), and 0.44 and
0.37 for ceftriaxone subjects. Therefore, it is likely that
the effect size of a treatment such as Ph1/2 would be in
the range of 0.25–0.35. Table 3 summarizes the samples
sizes that would be needed to achieve 80% or 90% power
using a 2-tailed test at a 5% level of significance with
either equal sample sizes or a 2:1 allocation of subjects to
treatment compared to a sham surgery that is placebo
arm.
Discussion
To date, ALS clinical trials of cellular therapies have
focused on safety, while efficacy remains to be established.
Here, we used available data from our Ph1/2 HSSC trans-
plantation trials in ALS participants to reconfirm safety
and perform post hoc comparisons to historical control
datasets to gain insight into potential efficacy over a 2-
year follow-up period. Given the HSSC Ph1/2 study
designs, the post hoc analysis was limited to ambulatory
limb-onset participants (n = 22), the subpopulation most
likely to benefit from cervical- or lumbar-targeted HSSC
treatments. Results indicate that this Ph1/2 participant
subpopulation had no significantly increased survival
compared to PRO-ACT and ceftriaxone historical con-
trols; however, survival curves comparing Ph1/2 with
these cohorts clearly deviated at 2 years. While this could
be the result of chance or a biased Ph1/2 population, it is
possible that stem cell efficacy was not apparent until
2 years. Supporting this view is the deviation of
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Figure 1. Kaplan–Meier survival curves. (A) Matched PRO-ACT (n = 1108) versus Ph1/2 (n = 21) participants: during follow-up, 239 deaths were
observed in the PRO-ACT group, 11 in the Ph1/2 group (Wilcoxon P = 0.996, log-rank 0.203). (B) Matched ceftriaxone (n = 177) versus Ph1/2
(n = 20) participants: during follow-up, 84 deaths were observed in the ceftriaxone group, 11 in the Ph1/2 group (Wilcoxon P = 0.877, log-rank
0.297). PRO-ACT, Pooled Resource Open-Access ALS Clinical Trials.
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ALSFRS-R scores, with statistically significant higher
scores in the Ph1/2 subpopulation compared to PRO-
ACT and ceftriaxone controls at 18 and 12 months,
respectively. The ALS/SURV statistic also highlights func-
tional differences between the Ph1/2 and comparison
cohorts; the median Ph1/2 participant was alive with dis-
ability whereas the median participant in the PRO-ACT
and ceftriaxone cohorts had died. These analyses collec-
tively support continued evaluation of HSSC transplanta-
tion in ALS participants, and importantly, inform future
efficacy trial design.
The current report differs from our prior publication in
important ways.16 First, the prior publication included only
9 months of Phase 2 follow-up data, whereas this report
includes >3 years of follow-up data. This enables a more
thorough evaluation of safety and long-term outcomes.
These long-term data highlight differences in survival out-
comes after the 2-year mark between the Ph1/2 cohort and
historical controls, indicating that the effect of HSSCs may
best be measured at >1–2 years post treatment and thereby
supporting the need for long-term clinical trials and
informing study design for a future trial. Additionally, the
current long-term follow-up data allows for the investiga-
tion of efficacy windows, which if replicated in a future
study would suggest that treatment provided early in dis-
ease is most optimal for allowing HSSCs time to provide a
disease modifying benefit. Second, the current analysis
focuses on a specific participant cohort from the Ph1/2 tri-
als that is ambulatory with limb-onset disease. This group
is most likely to benefit from HSSC transplantation given
the spinal-onset disease and transplant locations in the cer-
vical and/or lumbar segments. Third, we used a matching
technique for our specific participant cohort to identify his-
torical participants likely to have been selected into the
Ph1/2 studies, further strengthening the current analysis.
Fourth, we use an ALS/SURV statistic which enables com-
bined analysis of survival and function, thus summarizing
key ALS outcomes while accounting for losses to follow-up,
a limitation in long-term studies. Finally, using the ALS/
SURV statistic, we can perform the power calculation nec-
essary for a future trial.
While not applied previously in ALS to our knowledge,
ALS/SURV is similar to the CAFS and composite statistics
used in studies where endpoints involved nerve
Figure 2. ALS/SURV outcomes for matched Ph1/2 versus PRO-ACT and ceftriaxone cohorts: ALS/SURV outcomes are plotted by time. Each
marker represents the median measure (from Table 2). The bars encompass the 25th and 75th percentile. Values above the horizontal line reflect
ALSFRS-R whereas values below reflect survival. Graphs represent absolute measures for Ph1/2 versus PRO-ACT without losses to follow-up (A) or
with losses to follow-up (B), and absolute measures for Ph1/2 versus ceftriaxone without losses to follow-up (C) or with losses to follow-up (D).
For the Ph1/2 cohort, the lower quartile limit fell between a subject who was alive and a subject who had died; therefore, no value could be
estimated (open circle/†; B and D). ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale revised; PRO-ACT, Pooled Resource
Open-Access ALS Clinical Trials.
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conductions.23,24 When there is high mortality, combining
functional status with survival duration has greater com-
parative power and provides additional insight into
potential efficacy. Hence, ALS/SURV represents an ordinal
measure combining survival with ALSFRS-R. At the
extremes, if everyone died ALS/SURV would reduce to
comparing survival, and if everyone survived ALS/SURV
would compare function. Thus, it includes more compar-
ative information than either measure alone, and if func-
tion and survival are positively correlated (an underlying
assumption), ALS/SURV will have greater power than
either measure individually. Importantly, ALS/SURV anal-
yses were performed with and without imputation of par-
ticipants lost to follow-up. In a traditional intent-to-treat
randomized control study, participants are included in
the final analysis even if they drop out. Imputing losses
to follow-up based on ranks at the time of loss allows
these participants to be included in the final analysis. The
true outcome likely falls between the two analyses with or
without imputation. Finally, ALS/SURV composite data
were analyzed by nonparametric statistical methods using
the Mann–Whitney-Wilcoxon rank sum test, as well as
Table 2. ALS/SURV rankings over time for ambulatory, limb-onset participants.
(A) ALSFRS-R
Ph1/2 PRO-ACT Ph1/2 Ceftriaxone
N Mean (SD) N Mean (SD) t-test N Mean (SD) N Mean (SD) t-test
Baseline 21 36.5  5.4 1108 38.1  4.7 0.17 20 36.9  5.3 177 36.6  4.9 0.84
6 months 18 30.6  6.5 974 32.5  7.6 0.25 17 30.8  6.7 163 29.7  7.6 0.56
12 months 14 30.5  9 655 28.3  9.3 0.37 13 30.5  9.3 134 23.9  9.1 0.028
18 months 11 31.8  8.1 165 24.6  10.4 0.016 10 32.2  8.4 100 21  9.7 0.0021
24 months 11 30.1  8.6 86 24.0  10.2 0.048 10 30.7  8.8 58 19.2  9.5 0.0023
(B) Matched cohort ALS/SURV, no imputation
Ph1/2 PRO-ACT Ph1/2 Ceftriaxone
N Median (IQR) N Median (IQR) Wilcoxon N Median (IQR) N Median (IQR) Wilcoxon
Baseline 21 38 (31, 40) 1108 39 (35, 42) 0.12 20 38 (31, 40) 177 37 (34, 40) 0.95
6 months 20 29.5 (23, 35.5) 1012 33 (27, 38) 0.11 19 31 (22, 36) 168 30 (24, 35) 0.91
12 months 18 26.5 (16, 35) 792 26 (15, 35) 0.82 17 26 (16, 35) 155 21 (13, 30) 0.29
18 months 17 27 (1.2 yr, 36) 351 1.4 yr (0.8 yr, 24) 0.028 16 26 (1.1 yr, 36) 140 14 (1.3 yr, 24) 0.24
24 months 19 23 (1.2 yr, 33) 306 1.2 yr (0.8 yr, 10) 0.0038 18 19 (1.2 yr, 33) 115 1.7 yr (1.2 yr, 16) 0.14
(C) Matched cohort ALS/SURV, with imputation
Ph1/2 PRO-ACT Ph1/2 Ceftriaxone
N Median (IQR)1 N Median (IQR)1 Wilcoxon N Median (IQR)1 N Median (IQR)1 Wilcoxon
Baseline 21 38 (31, 40) 1108 39 (35, 42) 0.12 20 38 (31, 40) 177 37 (34, 40) 0.95
6 months 21 31 (24, 36) 1108 33 (26.5, 38) 0.25 20 32 (23, 36.5) 177 30 (24, 35) 0.86
12 months 21 26 (2, 31) 1108 25 (15, 34.5) 0.94 20 25.5 (2, 34) 177 21.5 (13, 29) 0.37
18 months 21 19.5 (1 yr, 34) 1108 3.5 (1 yr, 25.5) 0.18 20 19.5 (1.2 yr, 35) 177 13.5 (1.4 yr, 24) 0.22
24 months 21 15 (1.2 yr, 29) 1108 1.35 yr (0.9 yr, 16) 0.023 20 18 (1.2 yr, 31) 177 1.8 yr (1.35 yr, 17) 0.14
Note that ALS/SURV represents a combination of survival and ALSFRS-R score. When “yr” is specified, the value refers to survival time; that is, not
enough subjects were alive at that time point to estimate the median or quartile of ALSFRS-R at that time point and therefore the length of sur-
vival is used as the estimate. ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale revised; PRO-ACT, Pooled Resource Open-
Access ALS Clinical Trials; Ph1/2, Phase 1 and 2.
1Values are estimated from the closest subject, and not interpolated.
2The lower quartile limit fell between a subject who was alive and a subject who had died; therefore, no value could be estimated.
Table 3. Power estimate.
Effect size 0.25 0.30 0.35
Equal sample size, 80% power
(treatment, placebo)
255, 255 175, 175 130, 130
2:1 allocation, 80% power
(treatment, placebo)
380, 190 260, 130 200, 100
Equal sample size, 90% power
(treatment, placebo)
340, 340 235, 235 175, 175
2:1 allocation, 90% power
(treatment, placebo)
500, 250 350, 175 260, 130
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normal deviates as described for the power analysis, to
support other possible analyses such as modeling differ-
ences between groups.
ALS/SURV demonstrated that Ph1/2 participants main-
tained a higher percentage of baseline function versus
PRO-ACT and ceftriaxone participants, although these
improvements were only significant relative to PRO-ACT.
Sample size hinders potential assessment of an HSSC
dose–response effect in Ph1/2 participants. The power
analysis simulation for a future trial drew participants
from the matched Ph1/2 and ceftriaxone cohorts that had
similar inclusion criteria. As a single study, ceftriaxone
inclusion/exclusion criteria are well delineated, while the
large number of studies in PRO-ACT exhibit variable
inclusion/exclusion criteria. Results indicate that 255 par-
ticipants per group are required to achieve 80% power
with equal allocation to treatment and placebo, highlight-
ing the need for large numbers of willing participants,
potentially blinded to surgical therapy, to prove intrasp-
inal HSSC transplantation efficacy for ALS treatment.
Ph1/2 participants exhibited a significant difference in
ALSFRS-R at 24 months in both PRO-ACT and ceftriax-
one comparisons, but only for the PRO-ACT dataset for
ALS/SURV. PRO-ACT contains data between 1990 and
2013 and the ceftriaxone study occurred between 2006
and 2012; therefore, relative to the Phase 1 2009 start
date, ceftriaxone subjects had more contemporaneous
treatments given its more comparable start date. Collec-
tively, ALSFRS-R and ALS/SURV differences in our Ph1/2
cohort versus PRO-ACT and the ALSFRS-R and ALS/
SURV difference versus ceftriaxone supports continuing
investigation of HSSC intraspinal transplantation in ALS.
We acknowledge the potential bias of historical con-
trols,25 as bias can result from changes in patient manage-
ment, patient populations, study selection criteria,
diagnostic criteria, and patient willingness to participate
in trials. Our data also illustrate a limitation of historical
controls. Assuming that Ph1/2 participants had no differ-
ence in outcome compared to historical controls, and that
the ceftriaxone study showed no treatment benefit, one
would expect no differences in ALS/SURV between the
three cohorts. However, because the ALS/SURV summary
statistic shows a statistically significant difference between
Ph1/2 and PRO-ACT but not ceftriaxone, it raises the
possibility of a period effect. Furthermore, with the avail-
ability of edaravone, historical controls may have further
limitations due to changes in treatments.
This post hoc analysis has limitations. As previously
mentioned, the Ph1/2 data represent two trial phases
where participants received differing HSSC doses. While
we objectively defined our cohorts and only performed
the data analyses after matching and “locking” the com-
parison groups, a post hoc analysis may not represent the
true outcome. Furthermore, historical controls cannot
account for differences in ALS treatments over time. The
ceftriaxone study was performed at 59 study sites, whereas
most Ph1/2 participants were treated at two centers.
Therefore, investigator-initiated interventions, like using
noninvasive ventilation, in combination with the close
follow-up required in this study, may have improved
Ph1/2 participant survival as a result of maximal medical
management and not the cellular therapy. The study also
did not control for other possible variables, such as edu-
cation, socio-economic status, or family support, which
could all impact willingness to participate in clinical stud-
ies and/or outcomes. Finally, we acknowledge that the
subjects in our analysis cohort were 85% male, which
does not reflect true disease gender distribution ratios;
however, our goal and expectation for future studies is to
include more representative ratios of males and females
to ensure insight into any gender-specific outcomes.
Overall, the Ph1/2 studies were designed as safety trials
given the uncertain risk of escalating numbers and concen-
trations of intraspinal stem cell injections. Combined with
the small numbers of participants, and as Ph1/2 trials, these
studies were not designed to demonstrate efficacy. This post
hoc analysis, however, demonstrates that ambulatory ALS
participants receiving HSSCs exhibit significantly increased
ALSFRS-R scores relative to PRO-ACT and ceftriaxone his-
torical controls. In addition, they exhibited relatively better
outcomes using a combined survival/functional score ver-
sus PRO-ACT database participants. While these results
should not be overinterpreted as proof-of-benefit, the cur-
rent data support that this HSSC transplantation approach
should be tested for efficacy and provide the parameters
necessary to design a sufficiently powered, randomized,
sham surgery placebo-controlled study.
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